" Allergy medications overview
The arsenal of allergy drugs includes dozens of medications that relieve allergy symptoms when confronted with a trigger known as an allergen. That trigger could be something from a plant, such as polle"...
- Patient Information:
Details with Side Effects
Carcinogenesis, mutagenesis, impairment of fertility
Pemirolast potassium was not mutagenic or clasto-genic when tested in a series of bacterial and mammalian tests for gene mutation and chromosomal injury in vitro nor was it clastogenic when tested in vivo in rats.
Pemirolast potassium had no effect on mating and fertility in rats at oral doses up to 250 mg/kg (approximately 20,000 fold the human dose at 2 drops/eye, 40 μL/drop, QID for a 50 kg adult). A reduced fertility and pregnancy index occurred in the F1 generation when F0 dams were treated with 400 mg/kg pemirolast potassium during late pregnancy and lactation period (approximately 30,000 fold the human dose).
Teratogenic effects: Pregnancy Category C.
Pemirolast potassium caused an increased incidence of thymic remnant in the neck, interventricular septal defect, fetuses with wavy rib, splitting of thoracicvertebral body, and reduced numbers of ossified sternebrae, sacral and caudal vertebrae, and metatarsi when rats were given oral doses ≥ 250 mg/kg (approximately 20,000 fold the human dose at 2 drops/eye, 40 μL/drop, QID for a 50 kg adult) during organogenesis. Increased incidence of dilation of renal pelvis/ureter in the fetuses and neonates was also noted when rats were given an oral dose of 400 mg/kg pemirolast potassium (approximately 30,000 fold the human dose). Pemirolast potassium was not teratogenic in rabbits given oral doses up to 150 mg/kg (approximately 12,000 fold the human dose) during the same time period. There are no adequate and well-controlled studies in pregnant women. Because animal reproductive studies are not always predictive of human response, ALAMAST® (pemirolast potassium ophthalmic solution) ophthalmic solution should be used during pregnancy only if the benefit outweighs the risk.
Pemirolast potassium produced increased pre- and post-implantation losses, reduced embryo/fetal and neonatal survival, decreased neonatal body weight, and delayed neonatal development in rats receiving an oral dose at 400 mg/kg (approximately 30,000 fold the human dose). Pemirolast potassium also caused a reduction in the number of corpus lutea, the number of implantations, and number of live fetuses in the F1 generation in rats when F0 dams were given oral dosages ≥ 250mg/kg (approximately 20,000 fold the human dose) during late gestation and the lactation period.
Pemirolast potassium is excreted in the milk of lactating rats at concentrations higher than those in plasma. It is not known whether pemirolast potassium is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ALAMAST® (pemirolast potassium ophthalmic solution) ophthalmic solution is administered to a nursing woman.
Safety and effectiveness in pediatric patients below the age of 3 years have not been established.
Last reviewed on RxList: 12/30/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Alamast Information
Alamast - User Reviews
Alamast User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.